Replies to post #650280 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

And in that lies much truth.

This is what management have sold of own shares in 5 years



In comparison, what management sold in NVCR during 5 years.



And with Advent Bioservices having received NWBO shares as payment (see below) for many of their rendered services, I guess it's safe to say that quite a few - read: all - seems to believe that an NWBO share is a great currency.

During the year ended December 31, 2022, the Company issued an aggregate of 7.5 million shares of common stock at fair value of $5.9 million to Advent BioServices for services provided to the Company. This payment covers 8 milestones: 6 workstreams (Comparability, Stability, Potency, Product Profile, Fill/Finish, Mechanism of Action), and 2 required licenses for the Sawston facility (licenses from the Human Tissue Authority and from the MHRA for manufacturing for clinical trials and compassionate use cases)

The total amount paid by the Company to Advent during 2022 was approximately $12.7 million, which included $3.1 million for services rendered and invoiced in 2021 but not paid by the Company until 2022, and $9.6 million for services in 2022. In addition, during the year ended December 31, 2022, the Company paid, for 8 one-time milestones, an aggregate of $3.0 million in cash and 7.5 million shares at fair value of approximately $5.9 million